Executive Vice President, Chief Legal Officer · BIOMARIN PHARMACEUTICAL INC (BMRN)

G. Eric Davis

A named executive officer of BIOMARIN PHARMACEUTICAL in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$5,058,665

Salary $722,115Stock awards $2,880,871

FY2022: $5,189,142

6th of 6 named executive officers at Biomarin Pharmaceutical by FY2024 total.

6 named officers on file for BIOMARIN PHARMACEUTICAL, FY2024

G. Eric Davis’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • BMRN’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BIOMARIN PHARMACEUTICAL’s whole pay program stands against its peers

  • BIOMARIN PHARMACEUTICAL’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BMRN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 8, 2025 (DEF 14A).

Free

Get G. Eric Davis’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

G. Eric Davis compensation by year

BIOMARIN PHARMACEUTICAL Summary Compensation Table · all 2 fiscal years held
In US dollars, as BIOMARIN PHARMACEUTICAL reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2024
Salary$660,385$722,115
Bonus$0$0
Stock awards$3,104,558$2,880,871
Option awards$852,883$867,183
Non-equity incentive$532,650$565,500
Pension and deferred compensation$0$0
All other$38,667$22,996
Total$5,189,142$5,058,665

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOMARIN PHARMACEUTICAL INC DEF 14A filed April 8, 2025, accession 0001048477-25-000045, and prior-year filings.

How this page was built: the BIOMARIN PHARMACEUTICAL INC filed document, accession 0001048477-25-000045. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2025.

$5.2M
$5.1M
FY22
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU12,320$809,794—
RSU11,040$725,659—
RSU10,260$674,390—
RSU9,660$634,952—
RSU9,367$615,693—
PSU8,900$584,997—
PSU8,210$539,643—
RSU6,675$438,748—
RSU5,520$362,830—
PSU4,450$292,499—
PSU4,450$292,499—
RSU2,605$171,227—

Per the Outstanding Equity Awards at Fiscal Year-End table in BIOMARIN PHARMACEUTICAL INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 16 award rows shown.

BIOMARIN PHARMACEUTICAL’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Alexander HardyPresident and Chief Executive Officer$14,853,605
Henry FuchsPresident, Worldwide Research and Development$8,127,856
Gregory FribergExecutive Vice President and Chief Research & Development Officer$7,221,559
Cristin HubbardExecutive Vice President, Chief Commercial Officer$6,928,261
Brian MuellerExecutive Vice President, Chief Financial Officer$5,498,568
G. Eric Davis · this pageExecutive Vice President, Chief Legal Officer$5,058,665

The full BIOMARIN PHARMACEUTICAL compensation record

free company brief

This page is one person within BIOMARIN PHARMACEUTICAL's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the BIOMARIN PHARMACEUTICAL proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOMARIN PHARMACEUTICAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

G. Eric Davis's compensation dossier · One-time report. No refunds.